You searched for "regeneration"

2297 results found

Anatomical and functional outcomes following switching from aflibercept to ranibizumab in NARMD

This is a six-month, prospective, single-arm study in the UK and Germany. A total of 100 patients were enrolled (one in the primary failure group, 99 in the suboptimal treatment response group), treated three-monthly intravitreal ranibizumab injections (0.5mg), and then...

Wet AMD outcomes post cataract surgery

The authors present the findings of a retrospective study looking at the progression of wet age-related macular degeneration (AMD) in patients who underwent cataract surgery. They recruited a series of 111 patients of which 38 were men and 73 were...

The effects of anti-VEGF therapy for NvAMD on retinal vasculature

This retrospective consecutive case series examined 54 eyes of 54 treatment-naïve neovascular age-related macular degeneration (N-AMD) patients. Thirty-three eyes received intravitreal aflibercept injections, and 21 eyes received intravitreal ranibizumab injections with unaffected fellow eyes (54 eyes) as controls. All image...

OCT prognostic factors in AMD patients with peripapillary choroidal neovascularisation

In this retrospective study the authors aimed to investigate the correlation between optical coherence tomography (OCT) findings and visual acuity outcomes after treatment with intravitreal bevacizumab (IVB) injections for age-related macular degeneration (AMD) patients with peripapillary choroidal neovascularisation (PPCNV). Data...

Submacular haemorrhage associated with nAMD: A meta-analysis and meta-regression on use of tPA and anti-VEGFs

The aim of this study was to evaluate the efficacy of a combination of tPA and anti-VEGF in the treatment of submacular haemorrhage (SMH) associated with neovascular age-related macular degeneration (nAMD). A systematic review meta-analysis following PRISMA guidelines, focusing on...

OOC (Oxford Ophthalmological Congress) 2024

by Samuel Verdin, Editorial Coordinator, Eye News. We were recently ‘daan saaf’ in England for the wonderfully scientific and long-standing Oxford Ophthalmological Congress for their 107th year! Founding in 1909 by Robert W Doyne, the congress is guided by the...

Contrast sensitivity in myopic eyes

A classification system has been proposed for myopic maculopathy: grade 0 (no myopic retinal lesions), grade 1 (tessellated fundus), grade 2 (diffuse chorioretinal atrophy (CRA)), grade 3 (patchy CRA), and grade 4 (macular atrophy). Tessellated fundus is defined as the...

UK Eye Genetics Group (UK-EGG) 2024

by Mohammed Aslam, FY 3 Doctor, Calderdale and Huddersfield NHS Foundation Trust, UK. Founded in 2002, the UK EGG provides a hub to share knowledge on inherited eye disease and train the next generation of clinicians and scientists. This year’s...

Simulating the visual impairment symptoms of age-related macular degeneration in virtual reality

A new virtual reality application visually simulates age-related macular degeneration and demonstrates its progression over time including some Charles Bonnet syndrome hallucinations. Introduction Age-related macular degeneration (AMD) is the leading cause of blindness in developed countries with the prevalence of...

Anaesthetic drops abuse

A 67-year-old retired female nurse presented with persistent, bilateral, non-healing (>6 weeks) corneal ulcers and stromal ring infiltrates (Figures 1 and 2). The epithelial defects were the result of chemical burns caused by her contact lenses which had been stored...

A revolution in modern genetic testing for the clinical management of ocular disease

Recent years have seen a huge increase in our understanding of the genetic factors underlying a wide variety of eye diseases. This has included common conditions such as glaucoma and age-related macular degeneration, as well as those conditions which have...

Esme’s Umbrella announces the world’s first Charles Bonnet Syndrome Essay Prizes

Esme’s Umbrella (www.charlesbonnetsyndrome) has just announced the world’s first Charles Bonnet Syndrome Essay Prizes.